Skip to main content
SpringerLink
Log in

Sitagliptin

A Viewpoint by Mark S. Kipnes

  • Adis Drug Profiles
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006 Mar; 29(3): 531–7

    Article  PubMed  Google Scholar 

  2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 Nov 11; 368(9548): 1696–705

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes and Glandular Disease Research Associates, San Antonio, Texas, USA

    Mark S. Kipnes

Authors
  1. Mark S. Kipnes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kipnes, M.S. Sitagliptin. Drugs 67, 598–599 (2007). https://doi.org/10.2165/00003495-200767040-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767040-00009

Search

Navigation